A Second Chance at Life Thanks to Gene Sequencing at MSK
Wednesday, January 15, 2025
MSK is a world leader in precision oncology thanks to our donor community
A recent Newsweek story highlights the power of gene sequencing in cancer treatment.
Published in January 2025, it provides an overview of the promise of precision oncology — an approach that identifies and targets the gene mutations that drive each person's cancer.
The MSK donor community, including Cycle for Survival, has supported precision oncology from its inception.
It makes sense that Newsweek chose to interview six MSK physicians and scientists and tell the story of Michael Wolff, who is alive today because a decade ago his MSK physician identified the genetic cause of his very rare cancer and then found a drug to stop it.
Expanding precision oncology together
Michael’s story is remarkable. Most people with cancer today don’t benefit from precision oncology because there are hundreds of cancer-causing mutations and we don’t have drugs to target most of them yet. That’s why expanding precision oncology is one of the six strategic initiatives supported by The MSK Campaign: Leading Science. Changing Lives.
Donor support has made precision oncology what it is in 2025, and donor support will allow our scientists and physicians to one day identify all gene changes that cause cancer plus develop therapies to target each and every one. It's a lofty goal, but this is what the MSK Giving community does: tackle cancer’s biggest questions.
